Enliven Therapeutics Inc’s recent filing unveils that its Member of immediate family of Patel Anish acquired Company’s shares for reported $55175.0 on Jan 14 ’25. In the deal valued at $22.07 per share,2,500 shares were bought.
Then, Patel Anish bought 2,500 shares, generating $55,175 in total proceeds.
Before that, Patel Anish sold 21,700 shares. Enliven Therapeutics Inc shares valued at $524,697 were divested by the CHIEF OPERATING OFFICER at a price of $24.18 per share. As a result of the transaction, Patel Anish now holds 0 shares, worth roughly $0.0.
BTIG Research initiated its Enliven Therapeutics Inc [ELVN] rating to a Buy in a research note published on December 13, 2024; the price target was $42. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in early September with a ‘”a Buy”‘ rating. Robert W. Baird began covering ELVN with “an Outperform” recommendation on June 11, 2024. Mizuho started covering the stock on April 09, 2024. It rated ELVN as “a Buy”.
Price Performance Review of ELVN
On Tuesday, Enliven Therapeutics Inc [NASDAQ:ELVN] saw its stock fall -7.29% to $20.46. Over the last five days, the stock has lost -15.00%. Enliven Therapeutics Inc shares have fallen nearly -9.07% since the year began. Nevertheless, the stocks have risen 78.38% over the past one year. While a 52-week high of $30.03 was reached on 01/03/25, a 52-week low of $10.90 was recorded on 01/14/25. SMA at 50 days reached $24.60, while 200 days put it at $23.35.
Levels Of Support And Resistance For ELVN Stock
The 24-hour chart illustrates a support level at 19.55, which if violated will result in even more drops to 18.65. On the upside, there is a resistance level at 21.97. A further resistance level may holdings at 23.48. The Relative Strength Index (RSI) on the 14-day chart is 34.55, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.52, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 94.24%. Stochastics %K at 10.80% indicates the stock is a buying.
How much short interest is there in Enliven Therapeutics Inc?
A steep rise in short interest was recorded in Enliven Therapeutics Inc stocks on 2024-12-31, growing by 21709.0 shares to a total of 6.93 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-29 was 6.91 million shares. There was a rise of 0.31%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on March 29, 2023 when Jefferies began covering the stock and recommended ‘”a Buy”‘ rating along with a $27 price target.
